JPRN-UMIN000009573已完成未知
PC-SOD NE (PhaseIIa) -Repeated Dose Study in IPF patients- - PC-SOD NE (PhaseIIa)
TT Bio Pharma Co., LTD.0 个研究点目标入组 4 人开始时间: 2012年12月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Exclusion criteria involving similar diseases 1.Patients who's IPF was clearly caused by pharmaceuticals 2.Patients diagnosed with COPD or asthma or airway infection (2)Exclusion criteria due to previous treatment (3)Patients who are moderate intake of alcohol or alcoholics (4)Patients of chemical dependency (5)Patients who are smokers within a month(6)Patients are sensitive to any drugs (alldrugs prescribed or commercially available drugs) or have history of sensitivity to the drugs (7)Before 4 wee (8)Patients who participated in another clinical study within 4 months prior to the administration period of the study drug (9)Patients who are pregnant or possibly pregnant, or nursing (10)Patients who have taken PC-SOD previously in their medical history
研究者
相似试验
已完成
不适用
PC-SOD NE (Phase I) -Repeated Dose Study in healthy volunteersidiopathic pulmonary fibrosisJPRN-UMIN000008921TT Bio Pharma Co., LTD.8
已完成
1 期
PC-SOD NE(Phase I) -Single Dose Study in healthy volunteersidiopathic pulmonary fibrosisJPRN-UMIN000008920TT Bio Pharma Co., LTD.24
已完成
不适用
Phase II double blind trial of PC-SOD in patients with idiopathic interstitial pneumoniasIdiopathic interstitial pneumonias(GradeIII to IV)JPRN-UMIN000000752TT Bio-Pharma Co.,Ltd.45
已完成
不适用
Early Phase II clinical trial of PC-SOD -Study of the efficacy and safety of PC-SOD in patients with ulcerative colitisJPRN-UMIN000000753TT Bio-Pharma Co.,Ltd.40
进行中（未招募）
不适用
A multicentre, dose finding, phase II Study of CP-4055 in combination with Sorafenib in patients with metastatic malignant melanoma - CP4055-203A multicentre, dose finding, phase II Study of CP-4055 in combination with Sorafenib in patients with metastatic malignant melanomaEUCTR2007-000915-28-SEClavis Pharma ASA40